The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review.
Conclusions: This systematic review indicates that conbercept may achieve similar BCVA and CRT improvements as ranibizumab and aflibercept, with a superior rate of polyp regression at 12 months.
PMID: 32855818 [PubMed]
Source: Journal of Ophthalmology - Category: Opthalmology Tags: J Ophthalmol Source Type: research
More News: Eyes | Lucentis | Opthalmology | Polyps | Ranibizumab Injection | Statistics | Study | Vitamin A